Genmab is a Copenhagen antibody company that has quietly become one of the most profitable royalty franchises in oncology, and the central question for the stock is whether the DARZALEX royalty stream can carry the balance sheet through the riskiest phase of its own transition. The company is converting a partner-funded license business into a fully owned commercial operation, and that transition is being financed by the same cash it has been collecting for two decades.
The defining event is the Merus acquisition, closed in December 2025 for roughly $8.0 billion in cash. The deal added petosemtamab, a late-stage bispecific antibody for head and neck cancer, at a price of $97 per share, which reflected a substantial premium to the pre-announcement level. The mechanism is simple and consequential. Genmab funded the purchase with about $5.5 billion in new borrowings on top of its cash pile, swapping a debt-free, high-margin royalty balance sheet for a leveraged one. The strategic logic is to build a wholly owned growth portfolio that outlives the DARZALEX royalty. That logic is sound, but the interest cost of the deal, running at roughly $190 million per half, is now the largest drag on the income statement.
The tension sits between two clocks. The royalty engine is growing, with DARZALEX at $4,207 million in net sales for the second quarter alone, but every dollar of that growth is being consumed by operating expense expansion, integration charges, and debt service. First-half revenue rose 25% to $2,051 million. Operating cash flow, by contrast, fell to $54 million from $349 million a year earlier. That gap between the two numbers is the deal.
The timing trigger is the fourth quarter, when three readouts land in sequence. They are the EPCORE DLBCL-2 front-line epcoritamab study, the LiGeR-HN1 petosemtamab interim analysis, and the Rina-S ovarian cancer data, and each one tests a different part of the strategy.
Genmab's business has two distinct halves that used to be one. For twenty-five years the company operated as a discovery and licensing engine: it built antibody candidates on its proprietary platforms, handed them to big pharma, and collected royalties. DARZALEX, licensed to Johnson & Johnson, and Kesimpta, licensed to Novartis, are the two crown jewels. The DARZALEX arrangement pays Genmab royalties between 12% and 20% of worldwide net sales, with offsets for the subcutaneous formulation royalty J&J pays to Halozyme and for territories without Genmab patent coverage. That structure produces revenue that is high-margin, contractually protected, and nearly effortless to operate.
The strategic change is that Genmab is no longer willing to be only a royalty house. The Merus acquisition and the May 2024 ProfoundBio purchase, which brought Rina-S, mark a deliberate pivot toward owning the commercial economics of late-stage drugs end to end. CEO Jan van de Winkel's stated vision is to deliver "knock-your-socks-off" antibody medicines on Genmab's own terms, and the acquisition pipeline is the mechanism. The company now operates in three categories: royalty income from legacy partnerships, collaboration and net product sales from epcoritamab and Tivdak, and wholly owned late-stage programs in development.
The strategic logic of the pivot is defensible on one axis and fragile on another. DARZALEX royalty growth is real but it has a ceiling, because the underlying drug is entering its patent life and the royalty rate structure is fixed. A pure royalty company cannot compound growth beyond the underlying product's lifecycle. The pivot to wholly owned products is the answer, but it also means Genmab now carries the full cost of development, the full cost of a sales force, and the full cost of debt. The royalty engine funds the reinvention, but the reinvention is what the royalty engine was built to eventually replace.
The competitive context matters. The bispecific antibody space, where epcoritamab and petosemtamab compete, is crowded with assets from Amgen, AbbVie, Pfizer, and a long tail of smaller biotechs. Genmab's advantage is not that it has the best molecule, but that it has the cash flow to keep every late-stage program funded without diluting shareholders. That is a structural advantage, but it is only as strong as the royalty stream that funds it.
The moat is the platform, not any single molecule. Genmab's DuoBody bispecific antibody format, which links two antibody fragments into a single molecule, is the technology that produced epcoritamab and that underpins the entire late-stage pipeline. The platform advantage is that it has been validated in the clinic across multiple targets and multiple indications, which de-risks new candidates relative to a company building a bispecific from scratch. The company holds four antibody technologies, and the DuoBody format is the one that has converted into approved products.
Epcoritamab is the proof point. It is the first CD3xCD20 bispecific to show progression-free survival benefit in a pivotal monotherapy study for relapsed or refractory diffuse large B-cell lymphoma, and it is approved in more than 65 countries under the brand names EPKINLY and TEPKINLY. The EPCORE DLBCL-1 topline showed a hazard ratio of 0.74 against a chemo-immunotherapy control. That result was the first pivotal confirmation of the monotherapy approach, reported in early 2026. A later combination result cut the risk of progression or death by 60% in a chemo-free regimen. The clinical story is what makes the commercial case credible, and it is the outcome that most directly expands the addressable market.
The moat in the royalty business is contractual and legal, not technological. The DARZALEX royalty is protected by patent coverage in most major markets and by the offset structure with Halozyme. The royalty rate is locked between 12% and 20%, and the only variable is the underlying net sales number that J&J reports each quarter. That makes the royalty stream the most predictable component of Genmab's revenue, and it is the component that is being consumed.
Petosemtamab is the asset the Merus deal was really about. It is a bispecific antibody with two FDA Breakthrough Therapy Designations for head and neck cancer, in two Phase 3 trials, with an interim analysis expected in the fourth quarter of 2026. Management has guided to a launch by 2027 and to annual sales of at least $1 billion within a few years of approval. That is a bold claim for a drug in a category where the addressable market is estimated at roughly $4 billion. The moat here is the bispecific format and the Genmab commercial infrastructure, not the drug itself, and that distinction is important.
The first half of 2026 is the period that explains the whole investment case. Revenue rose 25% to $2,051 million, and the split between the two halves of the business tells the story. Royalty revenue grew 24% to $1,708 million, driven by DARZALEX and Kesimpta. Net sales of DARZALEX by J&J were $8,171 million in the first half, up 21% from the year-ago period. The royalty engine is working exactly as the contract says it should.
The problem is the bottom line. Operating profit was $555 million, up only 1% from a year earlier. Adjusted operating profit, after adding back the Merus integration charges and acquired intangible amortization, came to $656 million, up 18% from the prior-year period. The gap between the two numbers is the cost of the deal. Net profit fell 10% year over year in the second quarter, and the full first-half net profit of $303 million was flattered by a one-time tax benefit rather than by operating performance.
The balance sheet is the real story. Genmab took on $5.2 billion in borrowings to fund the Merus acquisition. The deal brought the equity ratio down from 80% before to 46% after. Operating cash flow fell from $349 million a year earlier to $54 million this year. Interest on the new debt, running at roughly $190 million per half, is now larger than the company's entire cost of product sales. The company still holds $1.5 billion in cash, which is meaningful, but the net debt position is a new and permanent feature of the balance sheet. The leverage is the defining feature of the post-merger Genmab, and it changes the risk profile of every other number in this report.
The expense structure is also changing. Adjusted operating expenses rose 28% to $1,270 million in the first half. The increase is driven by Rina-S and petosemtamab development and by the build-out of a global commercial team in preparation for their launches. This is the cost of the pivot, and it is permanent, not a one-time integration charge. The company is buying growth with margin, and the question is whether the growth justifies the margin sacrifice.
The fourth quarter of 2026 is the quarter that resolves most of the uncertainty. Three readouts land in sequence, and each one is a different kind of test. The EPCORE DLBCL-2 interim analysis, evaluating epcoritamab in combination with R-CHOP in front-line DLBCL, is the most commercially important because it moves epcoritamab from the relapsed setting into first-line treatment, where the patient population is several times larger. Management described the Phase 2 data behind this study as showing exceptional complete response rates, which is a strong claim, and the pivotal result is the test of whether that claim holds at scale.
The LiGeR-HN1 interim analysis for petosemtamab in first-line head and neck cancer is the second test, and it is the one that justifies the $8.0 billion price paid for Merus. The Phase 2 data showed a confirmed overall response rate of 36% in later-line head and neck cancer. Median overall survival in that setting ran at 11.4 to 12.5 months. That is respectable but not spectacular, and the first-line data is expected to be stronger. The interim analysis is a first look, not a full readout, and it is the kind of result that can move the stock 20% in either direction on data quality alone.
The Rina-S ovarian cancer data is the third test, and it is the one that carries the most legal risk. The AbbVie and ImmunoGen ITC case, which sought to block the import of Rina-S on trade-secret grounds, was terminated in July 2026 after AbbVie withdrew the complaint. That is a meaningful de-risking event, but the district court case in Seattle remains pending, and a loss there could still delay a U.S. launch. The Phase 3 data in platinum-resistant ovarian cancer is expected in the fourth quarter, and it is the asset that most directly competes with AbbVie's Elahere.
The execution risk that runs through all three is that Genmab is now a company that has to get late-stage commercialization right, not just late-stage science right. The royalty business required no sales force, no manufacturing at scale, and no launch execution. The wholly owned business requires all three, and the company is building those capabilities while simultaneously paying down $5.2 billion in debt. The 2026 guidance raise, with the revenue midpoint lifted to $4,425 million from the prior range, is a signal of management confidence. It is also a signal that the company is now committing to numbers that depend on execution it has not yet demonstrated at scale.
The largest risk is the DARZALEX royalty itself, and it is a risk that most of the valuation discussion treats as a tailwind. The royalty is growing, but it is growing on a fixed rate structure applied to a drug that is aging. J&J's net sales of DARZALEX were $14,351 million in 2025, up from a lower base the year before. The growth rate is moderating as the drug matures, and the offset structure with Halozyme means that as the subcutaneous formulation grows, a larger share of J&J's revenue goes to Halozyme rather than to Genmab. The royalty is a cash cow, but it is a cash cow with a known decline curve, and the decline curve is what the entire Merus bet is supposed to outrun.
The second risk is the debt load, and it is not the same as the first. The $5.2 billion in borrowings is not dangerous at current royalty levels, but it removes the financial flexibility that made Genmab a defensive holding. The company has $1.5 billion in cash against that debt, which is manageable. The interest cost of $190 million per half, however, is a real drag on free cash flow. If the petosemtamab launch is delayed or underperforms, the company would be carrying that debt without the growth asset that justified it. The deleveraging path depends on the royalty engine continuing to outperform, which is exactly the assumption the bear case disputes.
The third risk is competitive, and it is specific to the bispecific space. Epcoritamab's front-line DLBCL position is being tested by a field of bispecific and CAR-T competitors, and the Phase 3 data is judged against a higher standard than it would have been a year ago. The 60% reduction in progression risk in EPCORE DLBCL-4 is a strong result, but the control arm was R-GemOx, a chemo-immunotherapy regimen that many oncologists already regard as suboptimal. The real competitive test is against newer regimens, and that test is still ahead.
The fourth risk is the Rina-S legal overhang. The ITC case is closed, but the Seattle district court case is not. A loss on the trade-secret claim could enjoin U.S. sales of Rina-S, which would eliminate the largest single wholly owned asset in the pipeline. The probability of that outcome is low, but the consequence is asymmetric, and it is the kind of risk that is hard to price into a valuation.
The market is pricing Genmab at $32.47 per ADR, which gives a market capitalization of roughly $20.0 billion. The trailing P/E is 25.6, and the forward P/E is 20.4. The fifty-two week range runs from $23.62 to $35.43. The stock is trading in the upper third of that range after the Q2 guidance raise. The multiple is not cheap, but it is not the multiple the stock carried at its fifty-two week high, and the difference is the deal.
The right way to value Genmab is to split the company into two components and value each on its own economics. The royalty component, DARZALEX plus Kesimpta plus the smaller royalty streams, is a cash flow with a known decline curve. The DARZALEX royalty alone is generating roughly $2.7 billion per year at the midpoint of the 2026 guidance, and it is growing at mid-teens. A royalty stream with that growth profile and that contract protection is worth a multiple that reflects its quality, and the market is implicitly applying one. The wholly owned component, epcoritamab plus petosemtamab plus Rina-S, is a growth portfolio with a cost structure the company is still building, and it is worth a multiple that reflects the execution risk.
The bear case prices the royalty at a multiple that assumes the decline curve starts sooner than management thinks, and it prices the wholly owned portfolio at a discount to the development-stage peers because of the debt load. That combination implies a value in the mid-$20s per ADR, which is roughly where the stock was at the start of the year. The bear case is not wrong about the royalty decline, but it underweights the fact that the wholly owned portfolio is already generating revenue. Epcoritamab alone brought in $312 million of global net sales in the first half, up 48% from the year-ago period.
The base case prices the royalty at a multiple that assumes the decline curve starts around 2028, in line with the patent life, and it prices the wholly owned portfolio at a discount to the development-stage peers that reflects the debt but not the execution risk. That combination implies a value in the low-$30s per ADR, close to where the stock trades, and it is the most likely outcome. The bull case assumes the decline curve is slower than the patent life implies, because the subcutaneous formulation and new indications extend the commercial life, and it prices the wholly owned portfolio at a premium to the development-stage peers because the petosemtamab launch is on track and the front-line epcoritamab data is strong. That combination implies a value in the high-$30s to low-$40s per ADR, the range the stock reached at its 52-week high, and it requires both the front-line epcoritamab data and the petosemtamab interim analysis to come in strong, which is a high bar but not an unreasonable one.
The market has the royalty right and the pivot wrong. It correctly prices DARZALEX as a growing but finite cash stream, and it correctly discounts the wholly owned portfolio for the debt and the execution risk. What it is wrong about is the timing. The pivot is not a bet on future assets, it is a bet on assets that are already in Phase 3, already have Breakthrough Therapy Designations, and already have an interim analysis scheduled for the fourth quarter of 2026. The market is applying a development-stage discount to a company that has already moved the riskiest assets from Phase 2 to Phase 3.
The strongest argument against the stock is the balance sheet, and it is the strongest argument because it is the one that does not depend on a clinical readout. The $5.2 billion in debt is a real cost, and the $190 million per half in interest is a real drag on free cash flow. If the petosemtamab launch is delayed, the company is carrying that debt without the asset that justified it, and the royalty engine has to carry the entire burden. That is a real risk, and it is the one that keeps the stock from trading at the top of its 52-week range.
The strongest argument for the stock is that the pivot is further along than the multiple suggests. Epcoritamab is generating $312 million in global net sales in the first half, up 48% year over year. The front-line Phase 3 data is the single most important commercial event in the company's history, and the petosemtamab interim analysis is the test of the Merus price. A strong result would validate the $8.0 billion outlay. The Rina-S ITC withdrawal removes the largest single legal risk in the portfolio, and the company has three catalysts in one quarter, with the multiple pricing all three as uncertain rather than as probable.
The variables that determine the outcome are the front-line epcoritamab Phase 3 result, the petosemtamab interim analysis, and the Rina-S district court outcome. If all three come in well, the stock is undervalued at $32.47. If the petosemtamab interim analysis is weak, the debt becomes the dominant story, and the stock is fairly valued. The TickerFile view is that the market is pricing the royalty at the right multiple and the pivot at too steep a discount, and the fourth quarter of 2026 is the quarter that closes the gap.